Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience. (5th May 2014)

• Record Type: Journal Article
• Authors: Schwaederle, Maria; Parker, Barbara A.; Schwab, Richard B.; Fanta, Paul T.; Boles, Sarah G.; Daniels, Gregory A.; Bazhenova, Lyudmila A.; Subramanian, Rupa; Coutinho, Alice C.; Ojeda-Fournier, Haydee; Datnow, Brian; Webster, Nicholas J.; Lippman, Scott M.; Kurzrock, Razelle
• Is Part Of: Oncologist. Volume 19:Number 6(2014)
• Page Start: 631
• Page End: 636
• Publication Date: 2014-05-05
• Subjects: Cancer -- Molecular tumor board -- Molecular profile -- Personalized -- Mutation; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2013-0405
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Objective: DNA sequencing tests are enabling physicians to interrogate the molecular profiles of patients' tumors, but most oncologists have not been trained in advanced genomics. We initiated a molecular tumor board to provide expert multidisciplinary input for these patients. Materials and Methods: A team that included clinicians, basic scientists, geneticists, and bioinformatics/pathway scientists with expertise in various cancer types attended. Molecular tests were performed in a Clinical Laboratory Improvement Amendments environment. Results: Patients ( n = 34, since December 2012) had received a median of three prior therapies. The median time from physician order to receipt of molecular diagnostic test results was 27 days (range: 14–77 days). Patients had a median of 4 molecular abnormalities (range: 1–14 abnormalities) found by next-generation sequencing (182- or 236-gene panels). Seventy-four genes were involved, with 123 distinct abnormalities. Importantly, no two patients had the same aberrations, and 107 distinct abnormalities were seen only once. Among the 11 evaluable patients whose treatment had been informed by molecular diagnostics, 3 achieved partial responses (progression-free survival of 3.4 months, ≥6.5 months, and 7.6 months). The most common reasons for being unable to act on the molecular diagnostic results were that patients were ineligible for or could not travel to an appropriately targeted clinical trial and/or that insurance would not cover the cognate agents. Conclusion: Genomic sequencing is revealing complex molecular profiles that differ by patient. Multidisciplinary molecular tumor boards may help optimize management. Barriers to personalized therapy include access to appropriately targeted drugs. Abstract : Genomic sequencing is revealing complex molecular profiles that differ by patient. A molecular tumor board was initiated to provide expert multidisciplinary input for patients with tumors. Results showed that multidisciplinary molecular tumor boards may help optimize management. Barriers to personalized therapy include access to appropriately targeted drugs.